StocksMedium•3 November 2026•
1 min read
ChemoMetec Raises 2026/27 Guidance Following Strong Preliminary Q1 Results
Key Facts
1ChemoMetec A/S raised its full-year 2026/27 revenue and EBITDA guidance following strong performance.
2The guidance upgrade was driven by strong performance during the first four months of the fiscal year.
ChemoMetec A/S raised its full-year 2026/27 revenue and EBITDA guidance following strong performance. Benzinga reported that the upgrade was driven by robust operational results during the first four months of the fiscal year, with the company now projecting revenue in the range of DKK 570-605 million.
Preliminary results for the first quarter of 2026/27 showed revenue increased by 28% to DKK 160.0 million, compared to DKK 124.6 million in the same period last year. EBITDA reached DKK 100.3 million with a margin of 63%, supported by higher-than-expected demand for instruments and a lower cost base.
The full financial results for ChemoMetec for the first quarter of 2026/27 are scheduled to be released on Thursday, November 5, 2026.